Figure 2.

GC7 synergizes with cetuximab to promote cell proliferation in epithelial HCC cell lines. A. The efficacy of GC7 in inhibiting eIF5A was confirmed by western blotting. B-F. The five HCC cell lines were treated with cetuximab, or combination of cetuximab with GC7. Cell viability was assessed by CCK-8 assays. G-K. EdU incorporation assay was performed to assess the number of cells in proliferation. EdU-positive cells represent proliferating cells. The concentrations of cetuximab were the IC₅₀ values in B-F panels. GC7 were treated for a fixed concentration of 10 μM (**, P<0.01).